A new role for combination therapy in lipid management

British Journal of Cardiology

Volumn 8, Issue 11, 2001, Pages

  Kastelein, J J P ^a   Van Dam, M J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Combination therapy; Dyslipidaemia; Ezetimibe; Hypercholesterolaemia; Statins

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450 INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PRAVASTATIN; PROBUCOL; PROTEINASE INHIBITOR; SIMVASTATIN; SITOSTANOL; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

ARTHRALGIA; CAUSE OF DEATH; CHOLESTEROL BILE LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; EUROPE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; INTESTINE FUNCTION DISORDER; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MYOPATHY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TIMED DRUG RELEASE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 0035192050     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
2. The Munster Heart Study (PROCAM). Results of follow-up at 8 years
3. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
4. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study
5. Low-density lipoproteins and risk for coronary artery disease
6. The Framingham Study: Its 50-year legacy and future promise
7. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
8. The antiatherogenic role of high-density lipoprotein cholesterol
9. The emergence of triglycerides as a significant independent risk factor in coronary artery disease
10. Epidemiology of hypertriglyceridemia and cardiovascular disease
11. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, pathophysiology and therapeutic aspects
12. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
13. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
14. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
16. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
19. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
20. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
21. Medical education - Communicating best practice
22. The therapeutic gap - Compliance with medication and guidelines
23. Use of cholesterol-lowering medications in the United States from 1991 to 1997
24. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: Importance of diet, exercise, weight control, and drug therapy
25. HMG-CoA reductase inhibitors and myotoxicity
26. Drug interactions of lipid-altering drugs
27. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
28. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
29. The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function
30. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin
31. The undertreatment of LDL-cholesterol: Addressing the challenge
32. Best practice - Ongoing polemics
33. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines
34. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. EUROASPIRE Study Group
35. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme
36. Hyperlipidaemia: Differences in management practices and attitudes in two regions in Europe - Sicily and the Stockholm area
37. A call to action
38. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
39. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program
40. Cholesterol biosynthesis and metabolism
41. Drugs used in the treatment of hyperlipoproteinemias
42. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk
43. Receptor-mediated mechanisms of lipoprotein remnant catabolism
44. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma
45. New molecular targets for cholesterol-lowering therapy
46. The role of diet and exercise in the statin era
47. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
48. Pleiotropic effects of statins in atherosclerosis and diabetes
49. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
50. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
51. The evolving role of statins in the management of atherosclerosis
52. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
53. Drug treatment of lipid disorders
54. Role of fibrates in the management of hypertriglyceridemia
55. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
56. Mechanism of action of fibrates on lipid and lipoprotein metabolism
57. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients
58. Regulation of cholesterol metabolism by dietary plant sterols
59. Orlistat, a new lipase inhibitor for the management of obesity
60. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study
61. Treatment challenges in hypercholesterolemia
62. Drug therapy for hypercholesterolemia in patients with cardiovascular diseae: Factors limiting achievement of lipid goals
63. Statins: Within-group comparisons, statin escape and combination therapy
64. Treatment of hyperlipidemia with combined niacin-statin regimens
65. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care
66. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
67. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
68. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
69. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety
70. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
71. Choosing drug therapy for patients with hyperlipidemias
72. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group
73. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocytes and inhibits enterocyte cholesterol uptake and absorption
74. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
75. Low density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption in 243 hypercholesterolemic subjects: Results of a dose-response study
76. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor
77. Effect of age on the pharmacokinetics of ezetimibe
78. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically
79. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo
80. Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin
81. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin
82. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol
83. The potent cholesterol absorption inhibitor, ezetimibe, ablates hypercholesterolemia and hypertriglyceridemia in a model of combined hyperlipidemia
84. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters